MedTrace Logo

VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma

NCT01830465 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2013-04-12

No results posted yet for this study

Summary

The aim of this study was to evaluate the efficacy and safety of the combination of Velcade and Rituximab in patients with relapsed Non Hodgkin's Follicular Lymphoma.

Conditions

  • Non Hodgkin's Follicular Lymphoma

Interventions

DRUG

Bortezomib (VELCADE)

1,3 mg/m2, intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of each 21 day cycle. Number of Cycles: 6.

DRUG

Rituximab

375 mg/m2 as intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.

Sponsors & Collaborators

  • Gruppo Italiano Studio Linfomi

    lead OTHER

Principal Investigators

  • Stefano Sacchi, MD · Gruppo Italiano Studio Linfomi

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2008-08-31
Completion
2011-05-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01830465 on ClinicalTrials.gov